2006Guoji yiyao weisheng daobaoRequires access

Hydroxycamptothecin Combining with Lifein In Treatment Of Malignant Pleural And Petitoneal Effusion

李宇清, 梅开勇, 江素华, 曾波航

Open publisher page 0 citations

Abstract

目的 探讨羟基喜树碱联合力尔凡腔内化疗治疗恶性胸腹水的临床疗效.方法对经影像学检查及病例细胞学证实为癌症所致恶性胸腹水的30例患者尽量抽取胸腹水后,注入羟基喜树碱20mg,力尔凡30mg,每周1次,共3~4周.结果CR5例,PR18例,近期有效率为了76.7%,不良反应轻微.结论羟基喜树碱联合力尔凡治疗恶性胸腹水有协同作用,能增强患者的细胞免疫功能,同时减少恶性胸腹水,提高晚期癌症患者的生存质量。

About this research paper

What this paper is about

目的 探讨羟基喜树碱联合力尔凡腔内化疗治疗恶性胸腹水的临床疗效.方法对经影像学检查及病例细胞学证实为癌症所致恶性胸腹水的30例患者尽量抽取胸腹水后,注入羟基喜树碱20mg,力尔凡30mg,每周1次,共3~4周.结果CR5例,PR18例,近期有效率为了76.7%,不良反应轻微.结论羟基喜树碱联合力尔凡治疗恶性胸腹水有协同作用,能增强患者的细胞免疫功能,同时减少恶性胸腹水,提高晚期癌症患者的生存质量。

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

目的 探讨羟基喜树碱联合力尔凡腔内化疗治疗恶性胸腹水的临床疗效.方法对经影像学检查及病例细胞学证实为癌症所致恶性胸腹水的30例患者尽量抽取胸腹水后,注入羟基喜树碱20mg,力尔凡30mg,每周1次,共3~4周.结果CR5例,PR18例,近期有效率为了76.7%,不良反应轻微.结论羟基喜树碱联合力尔凡治疗恶性胸腹水有协同作用,能增强患者的细胞免疫功能,同时减少恶性胸腹水,提高晚期癌症患者的生存质量。

Key concepts: Malignant pleural effusion, Pleural effusion, Medicine, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Hydroxycamptothecin Combining with Lifein In Treatment Of Malignant Pleural And Petitoneal Effusion — Research Paper | ScholarLens